182 related articles for article (PubMed ID: 24461654)
1. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
Tümmler B
Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
3. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
Hayes D; Long FR; McCoy KS; Sheikh SI
Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
[No Abstract] [Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
van Koningsbruggen-Rietschel S; Naehrlich L
Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
[No Abstract] [Full Text] [Related]
5. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
6. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis, ivacaftor, and the Arg117His-CFTR mutation.
Accurso FJ
Lancet Respir Med; 2015 Jul; 3(7):498-9. PubMed ID: 26170070
[No Abstract] [Full Text] [Related]
8. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
9. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
10. Pulmonology: CFTR modulators for cystic fibrosis.
Bertoncini E; Colomb-Lippa D
JAAPA; 2013 Feb; 26(2):59-60. PubMed ID: 23409389
[No Abstract] [Full Text] [Related]
11. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
12. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
[No Abstract] [Full Text] [Related]
13. Ivacaftor.
Davis PB; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Apr; 11(5):349-50. PubMed ID: 22543461
[No Abstract] [Full Text] [Related]
14. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
15. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
Ong T; Ramsey BW
Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
[TBL] [Abstract][Full Text] [Related]
16. Ivacaftor imaging response in cystic fibrosis.
Hoare S; McEvoy S; McCarthy CJ; Kilcoyne A; Brady D; Gibney B; Gallagher CG; McKone EF; Dodd JD
Am J Respir Crit Care Med; 2014 Feb; 189(4):484. PubMed ID: 24528318
[No Abstract] [Full Text] [Related]
17. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
[No Abstract] [Full Text] [Related]
18. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.
Hull J
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S2-8. PubMed ID: 22688363
[No Abstract] [Full Text] [Related]
20. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
[Next] [New Search]